Taltz (ixekizumab) gets EU approval for Psoriasis

[Fred]

Following on from this report Taltz (ixekizumab) gets FDA approval for Psoriasis  Taltz (ixekizumab) has now also been given approval for psoriasis in the EU.

Quote:

---

Lilly is expecting to start rolling out Taltz in EU countries from this summer and through to the end of 2018, taking into account the typical cycle times for reimbursement assessment.

The approved dosing regimen for Taltz is a 160mg subcutaneous injection, followed by an 80mg injection every two weeks for 12 weeks and then a maintenance dose of 80mg each month. In trials, around 90% of patients treated with Lilly's drug had a 75% or more clearance in skin lesions after 12 weeks, with the majority (80%) showing clear or almost clear skin.

While second to market after Cosentyx, some clinicians say the phase III data for the two drugs suggest that Taltz may have some efficacy advantages over Novartis' product - though no head-to-head comparison is available - and could allow it to mount a strong challenge.

Source: pmlive.com

[jiml]

Even more good news if this is supposed to be better than Cosentyx it should do well as Cosentyx has a great success rate

I look forward to seeing this prescribed in the uk .....it gives more hope for the future for us sufferers

[Grizzly Bear]

This is good news

Hopefully, bin that nasty mtx stuff

[Fred]

Added it to the list: Biological Treatments For Psoriasis

That's now 8 Bio's available.

[jiml]

Added it to the list: Biological Treatments For Psoriasis

That's now 8 Bio's available.

Brilliant it's great to see the expanding arsenal of treatments.....the newer bios are proving very effective so it's good to see the numbers increasing, as some of the early ones seem to struggle to work for long,or for people to tolerate

[Fred]

Added it to the list: Biological Treatments For Psoriasis

That's now 8 Bio's available.

Brilliant it's great to see the expanding arsenal of treatments.....the newer bios are proving very effective  so it's good to see the numbers increasing, as some of the early ones seem to struggle to work for long,or for people to tolerate

Yes the future is looking good, and I'm sure those lagging behind will be playing catchup.

[Caroline]

Interesting this also heads for IL-17, like cosentyx. This receptor may thus be an important one in the area of psoriasis.

Quote from a study:

Quote:

---

We also analyzed direct changes in cytokine production in response to anti-CD3 stimulation (0.5 μg/ml for 24 h) with 10 μM DMF or vehicle using ELISPOT technology. This showed a significantly reduced production of IL-2 and IL-17, but no changes in IL-4 and IL-5 in C57BL6 splenocytes (Figure 3C) and a reduction in IL-2, IL-4, IL-5, IL-6, and IL-17 production in SJL splenocytes

So it also seems that DMF is doing something with all those IL's. But this is a study on mice.
Why does that me make me think of Jim ?

[mabcomp]

Even more good news if this is supposed to be better than Cosentyx it should do well as Cosentyx has a great success rate

I look forward to seeing this prescribed in the uk .....it gives more hope for the future for us sufferers  

Well we are IN the EU  at least at the moment

[jiml]

Even more good news if this is supposed to be better than Cosentyx it should do well as Cosentyx has a great success rate

I look forward to seeing this prescribed in the uk .....it gives more hope for the future for us sufferers  

Well we are IN the EU  at least at the moment

Yes you are right ( for the moment ) the eu has approved it but the uk go on the recommendation of NICE the GB watchdog that will either approve it and we might get it somewhere down the line

[Fred]

Health Canada has also granted approval for Taltz for the treatment of moderate-to-severe plaque psoriasis.